Clinical Trials Directory

Trials / Completed

CompletedNCT00262119

MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
1,300 (actual)
Sponsor
Medtronic Cardiac Rhythm and Heart Failure · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to test the impact of the managed ventricular pacing (MVP) mode and atrial preventive and antitachycardia pacing therapies on the reduction of a composite clinical outcome composed of any death, permanent atrial fibrillation, and cardiovascular hospitalizations.

Detailed description

Kristensen et al. reported that AAIR pacing reduces atrial fibrillation (AF) development compared to DDDR pacing in sinus node disfunction patients. Several authors have shown that, in patients with intact AV conduction, unnecessary chronic RV pacing can cause detrimental effects such as AF, left ventricular (LV) dysfunction and congestive heart failure. These findings arose the hypothesis that the non-physiologic nature of ventricular pacing may result in electrophysiological and LV remodeling changes that have potentially deleterious long-term effects. The MVP mode, present in the Medtronic pacemaker EnRhythm, provides atrial based pacing with ventricular backup. It operates in true AAI(R) mode, it provides ventricular backup in case of a single conduction loss and converts to DDD(R) mode in case of persistent loss of AV conduction. Aim of this study is to test the impact of the MVP pacing mode and atrial preventive and antitachycardia pacing therapies on the reduction of a composite clinical outcome composed by any death, permanent AF, cardiovascular hospitalizations.

Conditions

Interventions

TypeNameDescription
DEVICEPacemaker Medtronic EnRhythmPacemaker specific programming

Timeline

Start date
2006-02-01
Primary completion
2012-04-01
Completion
2013-04-01
First posted
2005-12-06
Last updated
2025-07-02
Results posted
2014-06-11

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT00262119. Inclusion in this directory is not an endorsement.